Ubs Group Ag Bio Cardia, Inc. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.52 - $2.8 $656 - $1,209	-432 Reduced 41.26%	615 $1,000
Q1 2023 May 12, 2023	SELL	$1.87 - $2.54 $12,717 - $17,274	-6,801 Reduced 86.66%	1,047 $2,000
Q4 2022 Feb 08, 2023	BUY	$1.61 - $32.1 $9,767 - $194,750	6,067 Added 340.65%	7,848 $16,000
Q3 2022 Nov 10, 2022	SELL	$0.24 - $30.3 $766 - $96,747	-3,193 Reduced 64.19%	1,781 $3,000
Q2 2022 Aug 10, 2022	BUY	$17.7 - $32.55 $58,056 - $106,763	3,280 Added 193.62%	4,974 $7,000
Q1 2022 May 16, 2022	SELL	$21.3 - $39.0 $87,734 - $160,641	-4,119 Reduced 70.86%	1,694 $4,000
Q4 2021 Feb 14, 2022	BUY	$25.65 - $46.05 $149,103 - $267,688	5,813 New	5,813 $11,000
Q3 2021 Nov 15, 2021	SELL	$42.6 - $58.65 $159,750 - $219,937	-3,750 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$48.9 - $74.85 $183,375 - $280,687	3,750 New	3,750 $15,000
Q1 2021 May 12, 2021	SELL	$51.3 - $78.15 $223,514 - $340,499	-4,357 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$28.8 - $100.5 $125,481 - $437,878	4,357 New	4,357 $15,000
Q2 2020 Jul 31, 2020	SELL	$31.8 - $77.64 $8,077 - $19,720	-254 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$33.0 - $85.2 $85,701 - $221,264	-2,597 Reduced 91.09%	254 $1,000
Q4 2019 Feb 14, 2020	BUY	$48.0 - $72.0 $136,848 - $205,272	2,851 New	2,851 $10,000

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $39.8M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.